• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用中空纤维膜模块对溶出-渗透系统进行表征及其在预测 BCS 分类药物体内渗透中的应用

Characterization of Dissolution-Permeation System using Hollow Fiber Membrane Module and Utility to Predict in Vivo Drug Permeation Across BCS Classes.

机构信息

Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, 21201, USA.

Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, 20993, USA.

出版信息

J Pharm Sci. 2022 Nov;111(11):3075-3087. doi: 10.1016/j.xphs.2022.07.002. Epub 2022 Jul 10.

DOI:10.1016/j.xphs.2022.07.002
PMID:35830941
Abstract

A dissolution-permeation system has potential to provide insight into the kinetic contributions of dissolution and permeation to overall drug absorption. The goals of the study were to characterize a dissolution-hollow fiber membrane (D-HFM) system and compare its resulting in vitro drug permeation constants (K) to in vivo clinical permeation constants (k), for four drugs in various Biopharmaceutics Classification System (BCS) classes. Model predictions for D-HFM were made based on derived mixing tank (MT) and complete radial (CRM) flow models and independent measurement of membrane permeability. Experimental D-HFM studies included donor flow rate and donor volume sensitivity studies, and drug permeation profile studies. Additionally, for the four drugs, Kfrom D-HFM system was compared to (k) from literature, as well as K values from side-by-side diffusion cell and dissolution/Caco-2 system. Results show progressive D-HFM system development as a dissolution-permeation tool. Results indicated that D-HFM models using MT or CRM provided close agreement between predicted and observed drug permeation profiles. Drug permeation in D-HFM system was volume dependent, as predicted. Favorably, more drug permeated through the D-HFM system (10-20% in 60 min) compared to side-by-side diffusion cell (1%) and dissolution/Caco-2 system (0.1%). K from D-HFM system was also closer to in vivo k; the two other in vitro models showed lower K. Overall, studies reflect that HFM module has potential to incorporate drug permeation into the in vitro assessment of in vivo tablet and capsule performance.

摘要

溶解-渗透系统有可能深入了解溶解和渗透对药物整体吸收的动力学贡献。该研究的目的是表征溶解-中空纤维膜(D-HFM)系统,并将其体外药物渗透常数(K)与四种不同生物药剂学分类系统(BCS)类别药物的体内临床渗透常数(k)进行比较。基于衍生的混合罐(MT)和完全径向(CRM)流动模型以及独立测量的膜渗透性,对 D-HFM 进行了模型预测。实验 D-HFM 研究包括供体流速和供体体积敏感性研究以及药物渗透曲线研究。此外,对于这四种药物,D-HFM 系统的 Kfrom 与文献中的(k)以及来自平行扩散池和溶解/Caco-2 系统的 K 值进行了比较。结果表明,D-HFM 系统作为溶解-渗透工具不断发展。结果表明,使用 MT 或 CRM 的 D-HFM 模型在预测和观察到的药物渗透曲线之间提供了很好的一致性。D-HFM 系统中的药物渗透与体积有关,如预测的那样。有利的是,与平行扩散池(1%)和溶解/Caco-2 系统(0.1%)相比,更多的药物渗透通过 D-HFM 系统(60 分钟内渗透 10-20%)。D-HFM 系统的 K 也更接近体内 k;另外两种体外模型显示出较低的 K。总体而言,这些研究反映出 HFM 模块有可能将药物渗透纳入体内片剂和胶囊性能的体外评估中。

相似文献

1
Characterization of Dissolution-Permeation System using Hollow Fiber Membrane Module and Utility to Predict in Vivo Drug Permeation Across BCS Classes.采用中空纤维膜模块对溶出-渗透系统进行表征及其在预测 BCS 分类药物体内渗透中的应用
J Pharm Sci. 2022 Nov;111(11):3075-3087. doi: 10.1016/j.xphs.2022.07.002. Epub 2022 Jul 10.
2
Dissolution-Hollow Fiber Membrane (D-HFM) System to Anticipate Biopharmaceutics Risk of Tablets and Capsules.溶解-中空纤维膜(D-HFM)系统预测片剂和胶囊的生物药剂学风险。
J Pharm Sci. 2023 Mar;112(3):751-759. doi: 10.1016/j.xphs.2022.09.030. Epub 2022 Oct 4.
3
Qualification of In Vitro Dissolution Absorption System 2 (IDAS2) with Caco-2 and MDCK Cell Monolayers: Dose Sensitivity Study Using BCS Class I and III Drugs.体外溶解吸收系统 2(IDAS2)与 Caco-2 和 MDCK 细胞单层的鉴定:使用 BCS Ⅰ类和Ⅲ类药物的剂量敏感性研究。
Biol Pharm Bull. 2024;47(6):1123-1127. doi: 10.1248/bpb.b24-00150.
4
The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.生物药剂学分类系统:体内预测溶出度(IPD)方法和体外-体内相关性的子类。
Eur J Pharm Sci. 2014 Jun 16;57:152-63. doi: 10.1016/j.ejps.2014.01.009. Epub 2014 Jan 28.
5
Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio.定量生物药剂学分类系统:剂量/溶解度比的核心作用。
Pharm Res. 2003 Dec;20(12):1917-25. doi: 10.1023/b:pham.0000008037.57884.11.
6
Characterization of the absorption of theophylline from immediate- and controlled-release dosage forms with a numerical approach using the in vitro dissolution-permeation process using caco-2 cells.采用数值方法,利用Caco-2细胞体外溶出-渗透过程,对速释和控释剂型中茶碱的吸收进行表征。
Drug Dev Ind Pharm. 2005 May;31(4-5):397-404. doi: 10.1080/03639040500214589.
7
Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.生物豁免扩展至生物药剂学分类系统III类药品的可行性:西咪替丁
Clin Pharmacokinet. 2006;45(4):385-99. doi: 10.2165/00003088-200645040-00004.
8
Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS).生物药剂学分类系统(BCS)的评估及改进建议。
J Pharm Pharmacol. 2007 Jun;59(6):751-7. doi: 10.1211/jpp.59.6.0001.
9
In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.体外溶解度、溶出度和渗透性研究结合半机理模型,以研究右美沙芬从速释和缓释制剂中的肠道吸收情况。
Eur J Pharm Sci. 2015 Sep 18;77:303-13. doi: 10.1016/j.ejps.2015.06.012. Epub 2015 Jun 16.
10
Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test.难溶性药物的口服吸收:通过微型溶出试验对人体吸收分数的计算机模拟
Pharm Res. 2006 Jun;23(6):1144-56. doi: 10.1007/s11095-006-0162-4. Epub 2006 May 25.

引用本文的文献

1
Comparison of lipophilic and size-exclusion membranes: the effect of stirring and cyclodextrin in the donor compartment.亲脂性膜与尺寸排阻膜的比较:供体室中搅拌和环糊精的影响。
ADMET DMPK. 2025 Jul 5;13(4):2753. doi: 10.5599/admet.2753. eCollection 2025.
2
In Vitro-In Vivo Correlation Of Amorphous Solid Dispersion Enabled Itraconazole Tablets.无定形固体分散体伊曲康唑片的体外-体内相关性
Pharm Res. 2025 Mar;42(3):485-502. doi: 10.1007/s11095-025-03837-z. Epub 2025 Mar 11.